EVALUATION OF THE EFFECTIVENESS OF MODERN IMMUNOTHERAPY

Immune checkpoint inhibitors are the most promising treatment option for many histological subtypes of malignant tumors, providing a long objective response and an increase in overall survival. Currently, there is growing evidence of the specific heterogeneity of clinical and radiological responses to immunotherapy, such as pseudoprogression and hyperprogression. In connection with the presence of these phenomena, the clinicians have a serious question about the need to allocate a certain cohort of patients for whom therapy with immuno-oncological drugs will be most effective and safe. This review demonstrates research results describing mentioned phenomena.